Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from First-line fluoropyrimidine- versus gemcitabine-based chemotherapy for metastatic recurrence after resection of ampullary adenocarcinoma: A real-world analysis of the FFCD-AC cohort. Local targets link to admitted publications; unresolved targets remain external evidence.
The pathohistological subtype strongly predicts survival in patients with ampullary carcinoma
2019 · External reference
Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma
10.1186/1471-2407-8-170 · 2008 · External reference
Intestinal-type of differentiation predicts favourable overall survival: confirmatory clinicopathological analysis of 198 periampullary adenocarcinomas of pancreatic, biliary, ampullary and duodenal origin
10.1186/1471-2407-13-428 · 2013 · External reference
Tumors of the ampulla of vater: histopathologic classification and predictors of survival
10.1016/j.jamcollsurg.2008.01.028 · 2008 · External reference
A simple prognostic score to predict recurrence after pancreaticoduodenectomy for ampullary carcinoma: results from the French prospective FFCD-AC cohort
10.1016/j.esmoop.2024.103988 · 2024 · External reference
Role of adjuvant multimodality therapy after curative-intent resection of ampullary carcinoma
10.1001/jamasurg.2019.1170 · 2019 · External reference
Role of adjuvant chemotherapy in T2N0M0 periampullary cancers
10.1111/ajco.12612 · 2017 · External reference
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial
10.1001/jama.2012.7352 · 2012 · External reference
Ampullary adenocarcinoma, version 1.2023, NCCN clinical practice guidelines in oncology
10.6004/jnccn.2023.0034 · 2023 · External reference
Ampullary tumors: French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, ACHBT, AFC, SFRO, RENAPE, SNFCP, AFEF, SFP, SFR)
10.1016/j.dld.2024.04.027 · 2024 · External reference
Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater
10.1200/jco.2008.19.7145 · 2009 · External reference
A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy
10.1093/annonc/mdt191 · 2013 · External reference
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
10.1056/nejmoa1011923 · 2011 · External reference
Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study
10.1200/jco.21.00679 · 2022 · External reference
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine
10.1056/nejmoa1304369 · 2013 · External reference
Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study
10.1093/annonc/mdq038 · 2010 · External reference
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
10.1016/j.annonc.2022.10.506 · 2023 · External reference
Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
10.1016/j.annonc.2023.08.009 · 2023 · External reference
Clinical relevance of pancreatobiliary and intestinal subtypes of ampullary and duodenal adenocarcinoma: pattern of recurrence, chemotherapy, and survival after pancreatoduodenectomy
10.1016/j.pan.2019.01.019 · 2019 · External reference
The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater
10.1007/s12032-009-9351-4 · 2010 · External reference
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer
2022 · External reference
Advanced ampullary cancer: post-hoc analysis of the ABC-01, ABC-02, and ABC-03 clinical trials
2026 · External reference
Association of histopathologic phenotype of periampullary adenocarcinomas with survival
10.1001/jamasurg.2016.3466 · 2017 · External reference
Genomic sequencing identifies ELF3 as a driver of ampullary carcinoma
10.1016/j.ccell.2015.12.012 · 2016 · External reference
Ampullary cancers harbor ELF3 tumor suppressor gene mutations and exhibit frequent WNT dysregulation
10.1016/j.celrep.2015.12.005 · 2016 · External reference
Genomic profiling unlocks new treatment opportunities for ampullary carcinoma
10.1016/j.esmoop.2025.104480 · 2025 · External reference
